Get startedLog in
    Picture of Xeris Biopharma Holdings logo

    XERS — Xeris Biopharma Holdings News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousMid CapNeutral
    All News

    Brief: Xeris Biopharma Announces First Participant Dosed In A Phase 2 Clinical Study Of Its Investigational Subcutaneous Levothyroxine In Patients With Hypothyroidism

    Picture of Xeris Biopharma Holdings logoXeris Biopharma Holdings
    21/06/2023 12:04
    June 21 (Reuters) - Xeris Biopharma Holdings Inc
 XERS.O :
    * XERIS BIOPHARMA ANNOUNCES FIRST PARTICIPANT DOSED IN A
PHASE 2
CLINICAL STUDY OF ITS INVESTIGATIONAL SUBCUTANEOUS (SC)
LEVOTHYROXINE (XP-8121) IN PATIENTS WITH HYPOTHYROIDISM

Source text for Eikon:  ID:nBw8xVts2a 
Further company coverage:  XERS.O 

 ((reuters.briefs@thomsonreuters.com;))

    Recent news on Xeris Biopharma Holdings

    See all news